Literature DB >> 17392600

Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes.

E Carmina1, R A Lobo.   

Abstract

BACKGROUND: Serum DHEAS has been found to be elevated in some women with polycystic ovary syndrome (PCOS). We wished to determine whether this prevalence is different in women with androgen excess who have different phenotypes and to correlate these findings with various cardiovascular and metabolic parameters.
METHODS: Two hundred and thirty-eight young hyperandrogenic women categorized into various diagnostic groups were evaluated for elevations in serum DHEAS, testosterone, glucose, insulin, quantitative insulin-sensitivity check index (QUICKI), cholesterol, HDL-C, LDL-C, triglycerides and C-reactive protein (CRP). Data were stratified based on elevations in DHEAS.
RESULTS: Serum DHEAS was elevated in 39.5% for the entire group [36.7% in PCOS and 48.3% in idiopathic hyperandrogenism (IHA)]. In classic (C)-PCOS, the prevalence was 39.6% and in ovulatory (OV) PCOS it was 29.1%. These differences were not statistically significant. Women with elevated DHEAS had higher testosterone but lower insulin, higher QUICKI, lower total and LDL-cholesterol and higher HDL-cholesterol, p<0.01. Triglycerides and CRP were not different. This trend was greatest in women with C-PCOS.
CONCLUSIONS: The prevalence of adrenal hyperandrogenism, as determined by elevations in DHEAS, appears to be statistically similar in IHA, C-PCOS and compared to OV-PCOS. Metabolic and cardiovascular parameters were noted to be more favorable in those women who have higher DHEAS levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392600     DOI: 10.1007/BF03347408

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  25 in total

1.  Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements.

Authors:  Hidetaka Hougaku; Jerome L Fleg; Samer S Najjar; Edward G Lakatta; S Mitchell Harman; Marc R Blackman; E Jeffrey Metter
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-09-13       Impact factor: 4.310

2.  Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters.

Authors:  Enrico Carmina; Francesco Orio; Stefano Palomba; Rosa A Longo; Gaetano Lombardi; Rogerio A Lobo
Journal:  Fertil Steril       Date:  2005-08       Impact factor: 7.329

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS).

Authors:  Ashim Kumar; Keslie S Woods; Alfred A Bartolucci; Ricardo Azziz
Journal:  Clin Endocrinol (Oxf)       Date:  2005-06       Impact factor: 3.478

5.  Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men.

Authors:  Hiroaki Kawano; Hirofumi Yasue; Akira Kitagawa; Nobutaka Hirai; Toshiaki Yoshida; Hirofumi Soejima; Shinzo Miyamoto; Masahiro Nakano; Hisao Ogawa
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

6.  The prevalence and significance of elevated dehydroepiandrosterone sulfate levels in anovulatory women.

Authors:  D I Hoffman; K Klove; R A Lobo
Journal:  Fertil Steril       Date:  1984-07       Impact factor: 7.329

7.  Adrenal androgen excess in hyperandrogenism: relation to age and body mass.

Authors:  C Morán; E Knochenhauer; L R Boots; R Azziz
Journal:  Fertil Steril       Date:  1999-04       Impact factor: 7.329

8.  Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome.

Authors:  Enrico Carmina; Rogerio A Lobo
Journal:  Fertil Steril       Date:  2004-09       Impact factor: 7.329

9.  Is 11 beta-hydroxyandrostenedione a better marker of adrenal androgen excess than dehydroepiandrosterone sulfate?

Authors:  F Z Stanczyk; L Chang; E Carmina; Z Putz; R A Lobo
Journal:  Am J Obstet Gynecol       Date:  1991-12       Impact factor: 8.661

10.  A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease.

Authors:  E Barrett-Connor; K T Khaw; S S Yen
Journal:  N Engl J Med       Date:  1986-12-11       Impact factor: 91.245

View more
  14 in total

1.  Lipid profile in relation to anthropometric indices and insulin resistance in overweight women with polycystic ovary syndrome.

Authors:  Maryam Saghafi-Asl; Saeed Pirouzpanah; Mehranghiz Ebrahimi-Mameghani; Mohammad Asghari-Jafarabadi; Soudabeh Aliashrafi; Bita Sadein
Journal:  Health Promot Perspect       Date:  2013-12-31

Review 2.  Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis.

Authors:  Héctor F Escobar-Morreale; Manuel Luque-Ramírez; Frank González
Journal:  Fertil Steril       Date:  2010-12-17       Impact factor: 7.329

3.  Metabolic and carbohydrate characteristics of different phenotypes of polycystic ovary syndrome.

Authors:  Ebru Çelik; Ilgın Türkçüoğlu; Barış Ata; Abdullah Karaer; Pınar Kırıcı; Sevil Eraslan; Çağatay Taşkapan; Bülent Berker
Journal:  J Turk Ger Gynecol Assoc       Date:  2016-12-01

4.  Excess 11-Oxygenated Androgens in Women With Severe Insulin Resistance Are Mediated by Adrenal Insulin Receptor Signaling.

Authors:  Dalia Walzer; Adina F Turcu; Smita Jha; Brent S Abel; Richard J Auchus; Deborah P Merke; Rebecca J Brown
Journal:  J Clin Endocrinol Metab       Date:  2022-08-18       Impact factor: 6.134

Review 5.  Nonhuman primates as models for human adrenal androgen production: function and dysfunction.

Authors:  D H Abbott; I M Bird
Journal:  Rev Endocr Metab Disord       Date:  2009-03       Impact factor: 6.514

Review 6.  Fetal programming of adrenal androgen excess: lessons from a nonhuman primate model of polycystic ovary syndrome.

Authors:  David H Abbott; Rao Zhou; Ian M Bird; Daniel A Dumesic; Alan J Conley
Journal:  Endocr Dev       Date:  2008

7.  Hyperandrogenemia in polycystic ovary syndrome: exploration of the role of free testosterone and androstenedione in metabolic phenotype.

Authors:  Elisabeth Lerchbaum; Verena Schwetz; Thomas Rabe; Albrecht Giuliani; Barbara Obermayer-Pietsch
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

8.  Insulin resistance and endocrine-metabolic abnormalities in polycystic ovarian syndrome: Comparison between obese and non-obese PCOS patients.

Authors:  Parvin Layegh; Zohreh Mousavi; Donya Farrokh Tehrani; Seyed Mohammad Reza Parizadeh; Mohammad Khajedaluee
Journal:  Int J Reprod Biomed (Yazd)       Date:  2016-04

9.  Adrenocortical steroid response to ACTH in different phenotypes of non-obese polycystic ovary syndrome.

Authors:  Nese Cinar; Ayla Harmanci; Duygu Yazgan Aksoy; Kadriye Aydin; Bulent Okan Yildiz
Journal:  J Ovarian Res       Date:  2012-12-07       Impact factor: 4.234

10.  The effect of androgens on ovarian follicle maturation: Dihydrotestosterone suppress FSH-stimulated granulosa cell proliferation by upregulating PPARγ-dependent PTEN expression.

Authors:  Mei-Jou Chen; Chia-Hung Chou; Shee-Uan Chen; Wei-Shiung Yang; Yu-Shih Yang; Hong-Nerng Ho
Journal:  Sci Rep       Date:  2015-12-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.